ORA Research News - Monday, March 22, 2021
Metabolomics Resource at OUHSC
The survey link is: https://ouhsc.qualtrics.com/jfe/form/SV_82FtfmR44aXU9tI
Jolyn Fernandes, MS, Ph.D., was recently recruited to OUHSC as Assistant Professor of Pediatrics, and the Associate Director of Metabolomics at Laboratory for Molecular Biology and Cytometry Research. Dr. Fernandes is building high-resolution high-throughput Metabolomics infrastructure at OUHSC campus. Metabolomics platforms are yielding important new insights into normal physiological processes, in pathology of disease and in treatment outcomes across multidisciplinary fields of basic science and clinical translation including Pediatrics, Diabetes, Cancer, Obesity, Immunology, Aging and Environmental Science. Metabolites such as sugars, amino acids, lipids etc have varied and important roles as signaling molecules, energy intermediates, microbiome derived metabolites, immune regulators, nutrient and environmental sensors.
Dr. Fernandes has developed a short survey to capture the need for Metabolomics platforms at OUHSC from previous users who may have outsourced these capabilities and to inform new users of available resources in the near future. Please take a few minutes to address this quick one page survey to help identify metabolomics user interests across OU.
Faculty using the email distribution system for research recruitment will now automatically include OU-Norman faculty. If PIs do not wish for their approved recruitment email to go to OU-Norman faculty, they will need to let the IRB administrator know at the time of their request. We hope this increases visibility of the campus research enterprise and facilitates recruitment across campuses.
OUHSC HSC COVID-19 Return Plan - now the HSC COVID-19 Response Plan - effective February 16, 2021.
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Adoption and implementation of updated testing and quarantine/isolation protocols following employee and student return from international travel and from cruises, based on recent federal executive order requirements (Sections VIII, IX). Please note that under the new protocols, individuals returning from international travel or from domestic or international cruises will typically have to quarantine/isolate from campus for 7 calendar days and receive a negative test prior to return. Individuals traveling internationally or taking cruises must be prepared to take leave (paid or unpaid, as appropriate) during the quarantine/isolation period communicated by Student/Employee Health, particularly if their position or responsibilities are not approved for or appropriate for remote work. Students must be prepared to be away from academic and clinical responsibilities during the designated quarantine/isolation period.
Requirement that even those fully vaccinated must complete the online COVID-19 Screening and Reporting Tool (Sections VII, IX). At this time, the CDC has issued limited guidance on how completion of the COVID-19 vaccine series will impact exposure assessment. We will continue to monitor and will make adjustments to this requirement as needed.
The Travel FAQs and the instructions for when to complete the online COVID-19 Screening and Reporting Tool, have been updated. The Tool itself has already been updated to reflect the changes above.
Gathering Market Insight for Innovation and Commercial Development
Help us showcase Oklahoma bioscience.
You’re invited to attend an exclusive (and free!) lunch to learn more about OU research and how it can be used to enhance innovation.
Dr. Meredith Wilkerson and Dr. Gina McMillen will showcase how OTC promotes your research and expertise to leaders in the biotech and pharma industries. Leveraging industry feedback to de-risk your technology and avoid barriers to market entry will also be discussed.
Wednesday, March 31, 2021
12 – 1 p.m. (CST)
Online via ZOOM
To RSVP go to: https://oklahoma.zoom.us/meeting/register/tJUldequqzsrHdLjeDsjZm2U9V00_WlSgCK_
New Mandatory Training – Research Integrity
On January 8, 2021, Provost Sanders announced the new Research Integrity Office and new mandatory training at OUHSC. All individuals at OUHSC who conduct or oversee research, who are eligible to conduct or oversee research - including managing research accounts (administrative and/or financial aspects of research accounts), must complete the Research Integrity training by April 5, 2021. One online course is required to fulfill the training requirement: “Biomedical Responsible Conduct of Research”, offered through the CITI Program. This requirement is in addition to any other Responsible Conduct of Research (RCR) training that individuals may have taken to date and is separate from any academic program requirements for students or Postdoctoral Fellows. Individuals seeking training should go directly to the CITI Program website to first register, affiliate their CITI profile with OUHSC, and add the “Biomedical Responsible Conduct of Research” course in order to begin the online training. The course is composed of 13 modules that can be taken separately as schedules allow with a short quiz at the end of each module that must be passed with a score of 80%; CITI allows you to retake the quizzes if you do not obtain the minimum score required to pass. The course provides a summary of core topics in the Responsible Conduct of Research including collaborative research, fiscal responsibility, conflicts of interest, authorship, human subjects, research misconduct and more. A 1-page document is attached with a brief summary of instructions for how to register and add the required course on the CITI Program website from the OUHSC Research Integrity Office. Additional information regarding how to access the required training, frequency of training, and answers to common questions can be found at: https://research.ouhsc.edu/Research-Integrity or https://research.ouhsc.edu/Research-Integrity/Research-Integrity-Training-FAQs
IRB ANNOUNCEMENT: NEW! Process for OUHSC to Serve as the Single IRB (sIRB) for Multi-Site Research Studies
EFFECTIVE MARCH 1, 2021: The HRPP and IRB have launched a revamped single IRB process for investigators who wish to use OUHSC as the single IRB of record for multi-site research. The process required an update in iRIS to the HSC IRB Application that will be easier to use; and the development of a brand new submission form called the ‘Relying Site Form’. As part of this revamped process, investigators must submit a request to the HRPP by completing a “Reliance Request” in REDCap for HSC to serve as the sIRB. Separating the reliance request and reliance agreement from iRIS will allow the IRB to proceed with review of the research protocol. This new process is intended to provide a clear and separate workflow without impacting turnaround times for IRB review of the research protocol. More information about the process, including a link to the REDCap form, is available on the HRPP website and iRIS. Stay tuned for Single IRB Workshops via Zoom!
HRPP website: https://compliance.ouhsc.edu/HRPP/Whats-New/OUHSC-Campus
IRB ANNOUNCEMENT: NEW VERSION OF THE IRB APPLICATION PUBLISHED
EFFECTIVE MARCH 1, 2021: In addition to the sIRB changes in the IRB application, a branching error has been corrected. Section 825 – Demographics will appear for all studies, regardless of direct participant interaction. Therefore, all investigators and study personnel who work on applications in iRIS must verify that Section 825 has been completed before submitting a revised application to the IRB.
IMPORTANT: In order to view the application changes, ALL users must convert to the new version of the application when prompted in iRIS.
ORA Noon Conference offered via Zoom
March 30, 2021 at 1:00 pm
Topic: Writing the NIH Biosketch
The NIH biosketch provides an opportunity for each key person listed in an application to explain why they are well suited for their role in the project. This talk will address writing a compelling personal statement, touch on research products that may be included in the citations, discuss how to address factors that may have affected past productivity (for example, illness or family emergency), provide guidance on the contributions to science section, and present the guidelines for format and structure.
*Important Update: A discussion of the upcoming changes to the NIH biosketch announced on 03/12/2021 and that will take effect on May 25, 2021 will also be included.
Please register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.
COLLEGE OF MEDICINE ALUMNI ASSOCIATION: CALL FOR PROPOSALS
The College of Medicine Alumni Association is pleased to announces a call for proposals for COMAA Research Grants. The College of Medicine Research Fund was created with the proceeds from the first Evening of Excellence Alumni Research Dinner over 30 years ago. To date over $3.3 Million has been awarded. Successful applicants will be designated “College of Medicine Alumni Research Scholars.” Applications will be reviewed by a scientific panel whose composition will be determined on the types of applications received. Awards generally fall within the $20,000 to $45,000 range ($45,000 maximum request). Applications should be sent electronically to the mailbox: COMAA-Research@ouhsc.edu by 5 pm on Thursday, April 1, 2021. All applications must be routed through the Office of Research Administration and include the NIH face page (https://grants.nih.gov/grants/funding/phs398/fp1.pdf) signed by the appropriate ORA institutional official. If you should have any questions, please email Mary Beth Humphrey, MD, PhD, Associate Dean of Research College of Medicine, at email@example.com.
Office of Technology Commercialization presents four opportunities to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com). Successful applicants will receive $15K for project costs. Preference will be given to those with access to assays that utilize human-derived cells or equivalent and are applicable for drug discovery. Proposal template available upon request (submission deadline 4/2/21).
Takeda Pharmaceutical Company is seeking academic expertise for testing Takeda’s proprietary compounds in academic phenotypic cellular assays relating to:
- Gastroenterology: assays which represent GI motility or liver fibrosis disorders.
- Neuroscience: assays which represent neuromuscular and neurodegenerative disorders.
- Oncology: assays which represent cancer treatment using the anti-tumor immune response.
- Rare disease: assays which represent rare metabolic and hematology disorders.
PRESBYTERIAN HEALTH FOUNDATION GRANTS – REQUEST FOR APPLICATIONS
The Presbyterian Health Foundation (PHF) will fund $4.15M in grants for 2021. Information on the PHF Grant Programs for Spring 2021 and Guidelines and Application for each of the grant programs listed below may be found at https://research.ouhsc.edu/Resources/PHF-Funding-2021. All guidelines have been recently updated to reflect that funds may not be requested for student tuition and fees. If you have any questions, please email ORA4PHF@ouhsc.edu.
March 26, 2021
March 26, 2021
March 26, 2021
New Investigator Seed
(Requires nomination by College)
April 2, 2021
April 2, 2021
Clinician Scientist Development
April 9, 2021
April 9, 2021
April 30, 2021
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of
individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain
these are current and are posted on the lab door and inside the laboratory.
community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at: https://research.ouhsc.edu/Resources/COVID-Research-Updates
Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021 (NOT-OD-21-073)
Request for Information (RFI): Invitation to Comment on the Draft NIH INvestigation of Co-Occurring Conditions Across the Lifespan to Understand Down syndromE (INCLUDE) Down Syndrome Research Plan (NOT-HD-21-014)
Request for Information (RFI): Improving the Mental Health of Rural People (NOT-MH-21-190)
Notice of NIAMS Participation in NOT-EB-21-001 "Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health"
Notice of Change to update the FOA title for RFA-FD-21-029 "Alliance to Support Integrated Public Health System Activities (U2F) Clinical Trials Not Allowed" (NOT-FD-21-012)
Notice of Early Expiration of NOT-MH-21-075 Notice of Special Interest (NOSI) Regarding the Use of Human Connectome Data for Secondary Analysis (NOT-MH-21-210)
Notice of NINR Participation in PA-18-935, "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement/Clinical Trial Optional)" (NOT-NR-21-002)
Notice of Correction to Application Types Allowed for RFA-TR-21-010 Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy (NOT-GM-21-032)
Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise
Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health (NOT-HD-20-032)
Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards
Notice of Special Interest: Innovative Approaches or Technologies to Investigate Regional, Structural and Functional Heterogeneity of CNS Small Blood and Lymphatic Vessels in AD/ADRD (NOT-NS-21-039)
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least two months prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
AHRQ/PCORI Learning Health System Small Grant Pilot Program (PA-21-202) - Deadline June 16, 2022
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-21-122)
Deadline June 17, 2021 and October 19, 2021
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) (PAR-21-123)
Deadline June 17, 2021 and October 19, 2021
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) (PAR-21-124)
Deadline June 17, 2021 and October 19, 2021
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-21-163)
Deadline August 10, 2021 and February 9, 2022
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) (PAR-21-190)
Deadline November 8, 2021 and March 7, 2022
New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional) (PAS-21-150)
Deadline June 5, 2021 and October 5, 2021
Expanding the Opioids System Modeling Efforts to More Comprehensively Address Fentanyl, Stimulants Use, Polysubstance Use and Associated Outcomes (U01) Clinical Trials Not Allowed (RFA-FD-21-022)
Deadline May 17, 2021
Enhancing Innovations in Advanced Manufacturing Technologies for Vaccines against Influenza and Emerging Infectious Diseases (R01) Clinical Trials Not Allowed (RFA-FD-21-033) – Deadline May 18, 2021
Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) (RFA-MD-21-005) – Deadline May 3, 2021
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) (RFA-MD-21-006) - Deadline May 3, 2021
BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) (RFA-MH-21-130) – Deadline October 7, 2021
BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
(RFA-MH-21-135) – Deadline October 10, 2021 and June 15, 2022
Limited Competition to Convert the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Study Cohort to a Research Resource (R24 - Clinical Trial Not Allowed) (RFA-MH-21-170) - Deadline May 10, 2021
HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) (RFA-NS-21-015) - Deadline April 27, 2021 and June 22, 2021
HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) (RFA-NS-21-016) - Deadline April 27, 2021 and June 22. 2021
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)
(RFA-OD-21-003) – Deadline October 8, 2021 and August 8, 2022
Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)
(RFA-OD-21-004) - Deadline October 8, 2021 and August 8, 2022
Chan Zuckerberg Initiative – Pediatric Networks for the Human Cell Atlas – Deadline March 30, 2021